CRSP Relative Valuation
CRSP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRSP is overvalued; if below, it's undervalued.
Historical Valuation
CRISPR Therapeutics AG (CRSP) is now in the Overvalued zone, suggesting that its current forward PS ratio of 84.82 is considered Overvalued compared with the five-year average of -13.70. The fair price of CRISPR Therapeutics AG (CRSP) is between 38.83 to 50.48 according to relative valuation methord. Compared to the current price of 63.59 USD , CRISPR Therapeutics AG is Overvalued By 25.99%.
Relative Value
Fair Zone
38.83-50.48
Current Price：63.59
25.99%
Overvalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
3.08
P/B
Median3y
2.28
Median5y
3.06
-6.09
FCF Yield
Median3y
-7.20
Median5y
-3.20
Competitors Valuation Multiple
The average P/S ratio for CRSP's competitors is 39.11, providing a benchmark for relative valuation. CRISPR Therapeutics AG Corp (CRSP) exhibits a P/S ratio of 84.75, which is 116.69% above the industry average. Given its robust revenue growth of 71.63%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is CRISPR Therapeutics AG (CRSP) currently overvalued or undervalued?
What is CRISPR Therapeutics AG (CRSP) fair value?
How does CRSP's valuation metrics compare to the industry average?
What is the current P/B ratio for CRISPR Therapeutics AG (CRSP) as of Jul 19 2025?
What is the current FCF Yield for CRISPR Therapeutics AG (CRSP) as of Jul 19 2025?
What is the current Forward P/E ratio for CRISPR Therapeutics AG (CRSP) as of Jul 19 2025?